EGFR vs KRAS Trial Activity: What the Counts Mean
The 8 September 2026 index returned 691 recruiting cancer-study records for EGFR and 312 for KRAS. Both genes sit in the same signalling network, but the counts reflect different molecular questions and cannot be read as a head-to-head measure of therapeutic success.
Quick Answer
The 8 September 2026 index returned 691 recruiting cancer-study records for EGFR and 312 for KRAS. Both genes sit in the same signalling network, but the counts reflect different molecular questions and cannot be read as a head-to-head measure of therapeutic success.
Side-by-side comparison
EGFR is the receptor input; KRAS is a downstream molecular switch. Trial records can mention either for different reasons.
| Question | EGFR | KRAS |
|---|---|---|
| Pathway position | Receptor tyrosine kinase | RAS-family GTPase downstream |
| Common trial language | Mutation, expression, amplification, resistance | Allele-specific mutation and pathway dependence |
| 8 Sep 2026 count | 691 | 312 |
| Main caution | Multiple tumour and alteration contexts | G12C, G12D, G12V and other alleles are not interchangeable |
One Pathway, Different Intervention Points
Activated EGFR recruits signalling machinery that promotes RAS activation. KRAS then helps transmit the signal through RAF, MEK and ERK, with parallel connections to PI3K signalling.
A trial can therefore study an EGFR inhibitor, an EGFR mutation, downstream escape from EGFR blockade, a direct KRAS inhibitor or a combination designed to prevent pathway rebound.
Why the EGFR Query Is Broader
EGFR can be searched as a receptor target, mutation-defined driver, expression biomarker or resistance context across lung, colorectal, head-and-neck, brain and other cancers. KRAS records more often specify an exact allele because G12C, G12D and G12V require different drug designs and occur at different frequencies by tumour type.
A plain KRAS query captures many of those records, but programme titles may foreground the allele or drug name. Record-level review is required before attributing the numerical gap to research investment or biological tractability.
Feedback Links the Two Research Areas
Direct KRAS inhibition can release feedback and increase upstream receptor signalling. Conversely, activating KRAS can allow downstream signalling to persist when an upstream receptor is blocked.
This is why EGFR-plus-KRAS combinations appear in some tumour settings and why an apparent division between two gene searches can conceal shared studies.
How to Read Future Changes
A rise in KRAS matches could reflect new allele-specific agents, multi-selective RAS programmes or status changes in existing studies. An EGFR change could reflect new inhibitor generations, antibody combinations, resistance studies or edited registry terminology.
The useful signal is the direction and composition of change across repeated snapshots, followed by manual review of the records responsible.
Key Takeaways
- ·EGFR and KRAS counts describe connected but different research questions.
- ·Allele identity is especially important for interpreting KRAS programmes.
- ·Overlapping records and feedback biology make the counts unsuitable for a head-to-head efficacy claim.
Put these genes in pathway context
Frequently asked questions
What is the key idea in EGFR vs KRAS Trial Activity: What the Counts Mean?
The 8 September 2026 index returned 691 recruiting cancer-study records for EGFR and 312 for KRAS. Both genes sit in the same signalling network, but the counts reflect different molecular questions and cannot be read as a head-to-head measure of therapeutic success.
What should be kept with the result or mechanism?
EGFR and KRAS counts describe connected but different research questions. Allele identity is especially important for interpreting KRAS programmes. Overlapping records and feedback biology make the counts unsuitable for a head-to-head efficacy claim.
References
- 1EGFR gene record. NCBI Gene, 2026. NCBI
- 2KRAS gene record. NCBI Gene, 2026. NCBI
- 3Recruiting cancer studies mentioning EGFR. ClinicalTrials.gov API, 2026. ClinicalTrials.gov
- 4Recruiting cancer studies mentioning KRAS. ClinicalTrials.gov API, 2026. ClinicalTrials.gov
Continue Reading
The 10 Most Mentioned Cancer Genes in Recruiting Trials
3 min read
Why HER2 Appears Above EGFR in Recruiting Trial Searches
3 min read
EGFR Mutations in NSCLC: Testing, Inhibitors and Resistance
5 min read
KRAS G12C vs G12D: Similar Gene, Different Alterations
2 min read
KRAS Mutations: Constitutive MAPK Signalling and Targeted Therapy
6 min read
MAPK Pathway Resistance: A Framework for Reading Resistance Reports
2 min read
Choose your next research step
Move from this explanation into a gene profile, a pathway map, or the next evidence update.
EGFR has 600+ trials currently recruiting on ClinicalTrials.gov. The GeneAnalyses digest summarises the new and changed ones each day.